samedan logo
home > ebr > autumn 2021 > innovative technology revolutionises vaccine development
European Biopharmaceutical Review

Innovative Technology Revolutionises Vaccine Development

Vaccinations are the best way to prevent epidemics. However, pathogens evolve their structure frequently and rapidly, rendering current methods of vaccine development not fast enough, as demonstrated by the current COVID-19 pandemic.

BioCopy is revolutionising vaccine development with its innovative technology. Molecular changes in new or mutated pathogens can be identified within days, so that an adapted, optimal vaccine can be made quickly available to protect against upcoming pandemics. The basis of the BioCopy innovation is a biomolecule copier, which, in principle, is similar to photocopying – except that the pixels are made of DNA, RNA, or proteins. During vaccine development, the genetic information of a pathogen is transferred to a special cavity chip in such a way that each individual cavity contains a different fragment or mutation of the pathogen genome. Each cavity corresponds to an individual reaction chamber during the copying process – a ‘DNA pixel’. After adding a transcription/translation mix and sealing the cavity chip with a specially coated glass slide, each DNA pixel generates copies of itself as DNA, RNA, or protein. The copy product binds to the slide surface, creating a corresponding array. The resulting microarrays allow the analysis of thousands of spots (‘pixels’) simultaneously; this is done label-free and in real time using our single colour reflectometry (SCORE)- detection system. Therefore, kinetic parameters (e.g., KD, kon, and koff values) can be determined for each spot of the microarray.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

To learn more about our vision and current projects, visit our website at and follow us on LinkedIn

BioCopy GmbH
Dr Günter Roth I CEO
Elstraße 27 I 79312 Emmendingen
T: +49 174 7867919
Print this page
Send to a friend
Privacy statement
News and Press Releases

Webinar to present findings from unique multidisciplinary research trials

Practical insights into lactose-based DPI formulations, with and without magnesium stearate Lactose-based dry powder inhaled (DPI) formulations are already well established in the market for the treatment of asthma and COPD. There is now a growing trend towards developing DPI formulations that are ternary mixtures including magnesium stearate as well as lactose and active pharmaceutical ingredients (APIs). The market for formulations of this kind is expanding rapidly and offers huge scope for generic players. However, the successful delivery of the active ingredient into the lungs depends on numerous interconnected factors during the production process. Therefore, the smallest change in the formulation can have a major effect on the end result.
More info >>

White Papers
Industry Events

Pharma Integrates 2021

16 November 2021, VIRTUAL CONFERENCE

Now in its tenth year, Pharma Integrates is a unique event bringing together pharma and healthcare leaders across the Pharmaceutical pipeline to address their needs, to share insights and create debate on crucial topics that influence the future of patient outcomes.
More info >>



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement